Gpc-3 is a notable diagnostic, prognostic and a latent targeted therapy marker in hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 57, Issue 102-103, 2010, Pages 1285-1290

  Zou, Zhi Qiang ^d   Ding, Yu Ping ^a   Long, Bo ^a   Yu, Ji Guang ^a   Xu, Ai Ling ^a   Lang, Zhen Wei ^b   Zou, Sai Ying ^c   Liu, You De ^a   Ding, Kun ^a   Li, Yuan Yuan ^a  

^a Infectious Diseases Hospital in Yantai   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c LANZHOU GENERAL HOSPITAL   (China)

^d NONE

Author keywords

Diagnostic; Hepatocellular carcinoma; Marker; Prognostic; Targeted therapy

Indexed keywords

BETA CATENIN; CD81 ANTIGEN; GLYPICAN 3; WNT PROTEIN;

APOPTOSIS; ARTICLE; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; DIAGNOSTIC VALUE; GENE EXPRESSION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

ADENOMA; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GLYPICANS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79251537779     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Jakubovic BD, Jothy S: Glypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp Mol Pathol. 2007; 82:184-189.
2. Li M, Choo B, Wong ZM, et al: Expression of OCI-5/ glypican3 during intestinal morphogenesis: regulation by cell shape in intestinal epithelial cells. Exp Cell Res. 1997; 235:3-12.
3. Pilia G, Hughes-Benzie RM, MacKenzie A, et al: Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996; 12:241-247.
4. Neri G, Gurrieri F, Zanni G et al: Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet. 1998; 79:279-283.
5. Filmus J, Capurro M, Rast J: Glypicans. Genome Biol 2008; 9:224.
6. Stigliano I, Puricelli L, Filmus J, et al: Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. Breast Cancer Res Treat 2009; 114:251-262.
7. Hughes-Benzie RM, Pilia G, Xuan JY, et al: Simpson-Golabi-Behmel syndrome: genotype/phenotype analysis of 18 afected males from 7 unrelated families. Am J Med Genet. 1996; 66:227-234.
8. Filmus J: Glypicans in growth control and cancer. Glycobiol-ogy. 2001; 11:19R-23R.
9. Hippo Y, Watanabe K, Watanabe A, et al: Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64:2418-2423.
10. Nakatsura T, Yoshitake Y, Senju S, et al: Glypican-3, overexpressed specifically in human hepatocellular carcinoma is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16-25.
11. Ikuta Y, Nakatsura T, Kageshita T, et al: Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res 2005; 11:8079-8088. (Pubitemid 41698751)
12. Tania R, Masamichi K: Pathology of Early Hepatocellular Carcinoma: Conventional and Molecular Diagnosis. Semin Liver Dis 2010; 30:17-25.
13. Bowen L, Shirish P, William C, et al: Investigation of the role of Glypican 3 in liver regeneration and hepatocyte proliferation, Am J Pathol 2009; 175:717-724.
14. Block GD, Locker J, Bowen WC, et al: Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/ SF:EGF and TGF alpha in a chemically defined (HGM) medium. J Cell Biol 1996; 132:1133-1149.
15. Song HH, Shi W, Xiang YY, et al: The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem. 2005; 280:2116-2125.
16. Capurro MI, Xiang YY, Lobe C, et al: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005; 65:6245-6254.
17. De Cat B, Muyldermans SY, Coomans C, et al: Processing by roprotein onvertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol, 2003; 163(3):625-635.
18. Filmus J, Capurro M: The role of glypican-3 in the regulation of body size and cancer. Cell Cycle 2008; 7:2787-2790.
19. Kleeff J, Ishiwata T, Kumbasar A, et al: The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 1998; 102:1662-1673.
20. Midorikawa Y, Ishikawa S, Iwanari H, et al: Glypican-3, overexpressed inhepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer. 2003; 103:455-465.
21. Li M, Choo B, Wong ZM, et al: Expression of OCI-5/ glypican 3 during intestinal morphogenesis:regulation by cell shape in intestinal epithelial cells. Exp Cell Res. 1997; 235:3-12.
22. Torisu Y, Watanabe A, Nonaka A, et al: Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF. Cancer Sci 2008; 99:1139-1146.
23. Gonzalez AD, Kaya M, Shi W, et al: OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol. 1998; 141:1407-1414.
24. Cocquerel L, Kuo CC, Dubuisson J, et al: CD81-dependentbinding of hepatitis C virus E1E2 heterodimers. J Virol 2003; 77:10677-10683.
25. Hsu HC, Cheng W, Lai PL: Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997; 57:5179-5184. (Pubitemid 27498138)
26. Zhu ZW, Friess H, Wang L, et al: Enhanced glypican- 3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 2001; 48:558-564.
27. Capurro M, Wanless IR, Sherman M, et al: Glypican- 3: a novel serum and histochemical marker for hepatocellular carcinoma.Gastroenterology. 2003; 125:89-97.
28. Wang XY, Degos F, Dubois S, et al: Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006; 37:1435-1441.
29. Nakatsura T, Yoshitake Y, Senju S, et al: Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003; 306:16-25.
30. Sung YK, Hwang SY, Park MK, et al: Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci. 2003; 94:259-262. (Pubitemid 36575892)
31. Yamauchi N, Watanabe A, Hishinuma M, et al: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005; 18:1591-1598.
32. Man XB, Tang L, Zhang BH, et al: Upregulation of glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.Liver Int. 2005; 25:962-966.
33. Ligato S, Mandich D, Cartun RW: Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocyto-chemical study. Mod Pathol. 2008; 21:626-631.
34. Shafizadeh N, Ferrell LD, Kakar S: Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008; 21:1011-1018.
35. Libbrecht L, Severi T, Cassiman D, et al: Glypican-3 expression distinguish-es small hepatocellular carcinomas from cirrhosis, dysplastic nodules,and focal nodular hyperplasia-like nodules. Am J Surg Pathol. 2006; 30:1405-1411.
36. Wang XY, Degos F, Dubois S, et al: Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006; 37:1435-1441.
37. Chen ZM, Crone KG, Watson MA, et al: Identification ofa unique gene expression signature that differentiates hepatocellular adenoma from well-differentiated hepatocellular carcinoma. Am J Surg Pathol. 2005; 29:1600-1608. (Pubitemid 43754481)
38. Llovet JM, Chen Y, Wurmbach E, et al: A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis Gastroenterology. 2006; 131:1758-1767.
39. Anatelli F, Chuang ST, Yang XJ, et al: Value of glypican 3 immuno-staining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol. 2008; 130:219-223.
40. International Working Party: Terminology of nodular hepatocellular lesions. Hepatology 1995; 22:983-993.
41. Lennerz JK, Brunt EM, Dehner LP, et al: Observer variability in the histo-pathologic diagnosis of hepatocellular nodules [abstract]. Mod Pathol. 2008; 21(suppl 1):308.
42. Abdul-Al HM, Makhlouf HR, Wang G, et al: Glypican- 3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol. 2008; 39:209-212.
43. Capurro M, Filmus J: Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res. 2005; 65:372; author reply 372-373.
44. Hippo Y, Watanabe K, Watanabe A, et al: Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 2004; 64:2418-2423.
45. Hsu HC, Cheng W, Lai PL: Cloning and expression of a developmentally regulated transcript MXR 7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997; 57:5179-5184.
46. Zhou XP, Wang HY, Yang GS, et al: Cloning and expression of MXR7 gene in human HCC tissue. World J Gastroenterol. 2000; 6:57-60.
47. Luca D T, Annarita D, Jae Y S, et al: The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol, 2009; 50:746-754.
48. Wee A: Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl Immunohistochem Mol Morphol. 2006; 14:266-272.
49. Capurro M, Wanless IR, Sherman M, et al: Glypican- 3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125:89-97.
50. Nassar A, Cohen C, Siddiqui MT: Utility of glypican3 and survivin in ifferentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies. Diagn Cytopathol. 2009; 37(9):629-635.
51. Wang XY, Degos F, Dubois S, et al: Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006; 37:1435-1441.
52. Hirofumi S, Hitomi S, Manami S, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci, 2009; 100:1403-1407.
53. Hanlin L W, Florencia A, Qihui Z, et al: Glypican-3 as a Useful Diagnostic Marker; That Distinguishes Hepatocellular Carcinoma From Benign Hepatocellular Mass Lesions. Arch Pathol Lab Med 2008; 132:1723-1728.
54. Portolani N, Coniglio A, Ghidoni S, et al: Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006; 243:229-235.
55. Poon RT, Fan ST, Ng IO, et al: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89:500-507.
56. Sakon M, Umeshita K, Nagano H, et al: Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg 2000; 135:1456-1459.
57. Motomura Y, Ikuta Y, Kuronuma T, et al: HLA-A2 and A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol 2008; 32:985-990.
58. Komori H, Nakatsura T, Senju S, et al: Identification of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3- specificimmunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12:2689-2697.